This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Immunomic Therapeutics, Inc.
Drug Names(s): JCC-LAMPvax
JCC-LAMP-vax is a DNA vaccine intended to treat patients with mountain cedar allergy.
Lysosomal Associated Membrane Protein (LAMP) is a glycoprotein localized to the lysosomal MHC-II compartment in antigen-presenting cells (APCs). The LAMP-Vax DNA vaccine platform is taken up by APCs, which produce the protein sequence encoded by the DNA as a fusion protein with LAMP. By accessing the MHC-II immune pathway, the vaccine should convert the immune system response from an IgE response to an IgG response, resulting in a reduction in allergy symptoms.
Additional information available to subscribers only: